Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on ASTELLAS PHARMA INC
03:21a ASTELLAS PHARMA : and FibroGen Announce First Patient Treated in Phase 3 Studies..
07/14 ASTELLAS PHARMA : "Pharmaceutical Composition for Modified Use" in Patent Applic..
07/09DJCorrections & Amplifications -- WSJ
07/07 ASTELLAS PHARMA : Recent Findings from Astellas Pharma, Inc. Has Provided New Da..
07/06 ASTELLAS PHARMA : Named to FTSE4Good Sustainability Index for the Fifth Consecut..
06/28 ASTELLAS PHARMA : Farma Brasil Among Top 3 Workplaces in Brazilian Pharmaceutica..
06/23 ASTELLAS PHARMA : Findings from Astellas Pharma, Inc. Provides New Data about Th..
06/23 ASTELLAS PHARMA : The Institute of Medical Science, the University of Tokyo and ..
06/20 ASTELLAS PHARMA : NIH won't cut price of taxpayer-funded prostate cancer drug
06/16 ASTELLAS PHARMA : Excelra Enters into a Drug Repurposing Collaboration with Aste..
06/09 ASTELLAS PHARMA : and Medivation Initiate Phase III Trial of Enzalutamide in Pat..
06/09 ASTELLAS PHARMA : Excelra Enters into a Drug Repurposing Collaboration with Aste..
06/08 ASTELLAS PHARMA : Genentech, OSI to pay $67M over cancer drug allegations
06/07 ASTELLAS PHARMA : Genentec, OSI Pharma to pay $67M to resolve Tarceva false clai..
06/07 ROCHE : Pharmaceutical Companies to Pay $67 Million To Resolve False Claims Act ..
06/07 ASTELLAS PHARMA : Genentech, OSI to pay $67M over cancer drug allegations
06/07 GENENTECH, OSI TO PAY $67 MILLION OV : U.S. Justice Dept
06/06 ROCHE : Pharmaceutical Companies To Pay $67 Million To Resolve False Claims Act ..
06/03 ASTELLAS PHARMA : AND MEDIVATION INITIATE PHASE III TRIAL OF ENZALUTAMIDE IN PAT..
06/02 BAXALTA : Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights..
06/02 ASTELLAS PHARMA : Medivation and Astellas Initiate Phase III Trial of Enzalutami..
05/26 BAXALTA : Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights..
05/25DJSanofi Moves to Replace Medivation Board
05/23 ASTELLAS PHARMA : THE RESULTS FROM A ONE YEAR TREATMENT OF REPATHA PRESENTED AT ..
05/12 ASTELLAS PHARMA : Transplant Genomics Announces Immunosuppressive Clinical Trial..
05/12 ASTELLAS PHARMA : New Type 2 Diabetes Study Findings Have Been Reported by Inves..
05/10 Medivation succumbs to pressure to explore sale - sources
05/09 EXCLUSIVE - MEDIVATION SUCCUMBS TO P : sources
05/09 ASTELLAS PHARMA : Vical Reports First Quarter 2016 Financial Results
04/29DJSanofi Seeks Talks With Medivation Over $9.3 Billion Offer
04/28 Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation
04/28 ASTELLAS PHARMA : Co-sponsors C3 Prize
04/28 ASTELLAS PHARMA : Announces Changes to Representative Director and Audit & Super..
04/28DJSanofi Makes $9.3 Billion Bid for U.S. Cancer-Drug Maker
04/22 SEATTLE GENETICS : Agensys, Seattle Genetics Assigned Patent
04/21 ASTELLAS PHARMA : CHMP Issues Positive Opinion to Include New Data in European L..
04/21 NEW DRUG DEVELOPMENT STUDY FINDINGS : Role of...
04/21 ASTELLAS PHARMA : Amgen astellas biopharma and astellas introduce repatha® (evol..
04/11 ASTELLAS PHARMA : CHMP Issues Positive Opinion to Include New Data in European L..
04/11 ASTELLAS PHARMA : Certain media coverage related to Astellas
04/09 ASTELLAS PHARMA : Kaketsuken in talks to sell vaccine business
04/08 ASTELLAS PHARMA : CHMP Issues Positive Opinion to Include New Data in European L..
04/08 ASTELLAS PHARMA : Certain media coverage related to Astellas
04/07 ASTELLAS PHARMA : Findings from Astellas Pharma, Inc. in Combination Therapy Rep..
04/04 ASTELLAS PHARMA : Enters a New Collaborative Research Agreement with AIST to Dis..
04/04 ASTELLAS PHARMA : Establishment and Start of Operations of Malaysia Subsidiary a..
04/01 ASTELLAS PHARMA : and LEO Pharma Close Transaction to Transfer Global Dermatolog..
04/01 ASTELLAS PHARMA : Establishment and Start of Operations of Malaysia Subsidiary a..
04/01 ASTELLAS PHARMA : Enters a New Collaborative Research Agreement with AIST to Dis..
04/01 ASTELLAS PHARMA : and LEO Pharma Close Transaction to Transfer Global Dermatolog..
03/31 ASTELLAS PHARMA : Pivotal Phase III Trial of enzalutamide Initiated in Metastati..
03/29DJLawmakers Target Medivation Over Drug Prices
03/29 ASTELLAS PHARMA : Sanders, Welch, Leahy to NIH and HHS: Act Now on Drug Affordab..
03/29 ASTELLAS PHARMA : and Mitsubishi Tanabe Pharma Execute Agreement for Share of Co..
03/29 ASTELLAS PHARMA INC : ex-dividend day for final dividend
03/28 ASTELLAS PHARMA : Lawmakers to NIH and HHS: Act Now on Drug Affordability
03/25 ASTELLAS PHARMA : Pivotal Phase III Trial of enzalutamide Initiated in Metastati..
03/22 ASTELLAS PHARMA : Positive top-line results from phase 3 study evaluating romoso..
03/17 ASTELLAS PHARMA : Results of Open-Label Trial for CRESEMBA isavuconazonium sulfa..
03/17 ASTELLAS PHARMA : Kanyos Bio Raises USD16 Million in Venture Financing
03/16 ASTELLAS PHARMA : Selected as a Nadeshiko Brand Component for Excellence in Prov..
03/10 ASTELLAS PHARMA : Basilea announces that The Lancet Infectious Diseases publishe..
03/10 ASTELLAS PHARMA : Basilea announces that The Lancet Infectious Diseases publishe..
03/04 ASTELLAS PHARMA : Announces Personnel Changes (pdf 47KB)
03/03 ASTELLAS PHARMA : Reports on Pain from Astellas Pharma, Inc. Provide New Insight..
03/03 ASTELLAS PHARMA : Findings from Astellas Pharma, Inc. Has Provided New Data on M..
03/02 ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (pdf 41KB)
03/02 ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (pdf 92KB)
03/01 ASTELLAS PHARMA : Announces Management Structure Change
03/01 ASTELLAS PHARMA : Announces Personnel Changes and Organizational Change
03/01 ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (Under the provi..
03/01 ASTELLAS PHARMA : Announces Management Structure Change (pdf 70KB)
03/01 ASTELLAS PHARMA : Announces Personnel Changes and Organizational Change (pdf 47K..
02/29 ASTELLAS PHARMA : Receives Approval for a Supplemental New Drug Application for ..
02/25 MEDIVATION : FDA accepts to review sNDA for Xtandi in mCRPC
1  2  3  4  5  6Next
Advertisement
Financials ( JPY)
Sales 2017 1 335 754 M
EBIT 2017 280 000 M
Net income 2017 197 265 M
Finance 2017 480 085 M
Yield 2017 2,07%
P/E ratio 2017 17,80
P/E ratio 2018 16,43
EV / Sales 2017 2,33x
EV / Sales 2018 2,17x
Capitalization 3 591 500 M
More Financials
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 1 915  JPY
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yukihiko Sato President & Chief Executive Officer
Masafumi Nogimori Chairman
Yasumasa Masuda Senior Executive Officer & Head-Finance
Mitsunori Matsuda Senior Executive Officer & GM-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-2.94%34 389
JOHNSON & JOHNSON21.58%343 528
PFIZER INC.13.94%223 065
NOVARTIS AG-5.13%218 815
ROCHE HOLDING LTD.-9.62%217 668
MERCK & CO., INC.10.87%162 096
More Results